Abstract 9328: Pulmonary Vein Isolation Alone vs Additional Ablation in Heart Failure with Preserved Ejection Fraction
Pulmonalvenenisolation allein vs. zusätzliche Ablation bei Herzinsuffizienz mit erhaltener Ejektionsfraktion
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9328 ↗Auf einen Blick
Bei Patient:innen mit HFpEF und Vorhofflimmern war zusätzliche Ablation über die Pulmonalvenenisolation hinaus nicht mit besseren Rhythmus- oder klinischen Ergebnissen verbunden.
Fragestellung
Ist bei HFpEF bei Erstablation wegen paroxysmalem oder persistierendem Vorhofflimmern eine zusätzliche Ablation zu PVI mit besseren Langzeit-Outcomes verbunden als PVI allein?
Methode
Retrospektive Kohortenstudie in der TriNetX Research Network; Erwachsene mit HFpEF und Erstablation zwischen 1. Januar 2015 und 1. März 2025; 1:1 Propensity-Score-Matching; getrennte Analysen für paroxysmales und persistierendes AF.
Ergebnisse
Nach Matching blieben 422 Patient:innen je Gruppe im paroxysmalen und 2.837 je Gruppe im persistierenden AF-Kollektiv. Es gab keine signifikanten Unterschiede bei Rezidiv, Mortalität, Hospitalisierung oder Schlaganfall; z. B. HR 1,09 (95 %-KI 0,88–1,34) und 1,10 (95 %-KI 0,90–1,34) im paroxysmalen Kollektiv.
Schlussfolgerung der Autor:innen
Bei HFpEF und Erstablation wegen paroxysmalem oder persistierendem AF war zusätzliche Ablation über PVI hinaus nicht mit geringerer Rezidivrate oder besseren wichtigen klinischen Ergebnissen verbunden.
Kernaussagen
- PVI plus zeigte keinen Vorteil gegenüber PVI allein.
- Keine Unterschiede bei Rezidiv, Mortalität, Hospitalisierung oder Schlaganfall.
- Analyse getrennt für paroxysmales und persistierendes AF.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Alex El Darzi und 16 weiteren Autor:innen.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) frequently undergo catheter ablation, but the optimal ablation strategy in this population remains unclear. Although adjunctive ablation beyond pulmonary vein isolation (PVI plus) is often used in patients with more advanced atrial disease, its value in HFpEF has not been specifically established. Hypothesis: We hypothesized that, among patients with HFpEF undergoing first-time catheter ablation for paroxysmal or persistent AF, PVI plus adjunctive ablation would not be associated with improved long-term rhythm or clinical outcomes compared with PVI alone.
Methods
We performed a retrospective cohort study using the TriNetX Research Network. Adult patients with HFpEF who underwent first-time catheter ablation for AF between January 1, 2015 and March 1, 2025 were identified. Patients were grouped according to whether they underwent PVI alone or PVI plus additional ablation during the index procedure. Separate analyses were performed for paroxysmal and persistent AF. Baseline characteristics, including demographics, comorbidities, arrhythmia history, medication use, and echocardiographic variables, were assessed and balanced using 1:1 propensity score matching. The composite recurrence endpoint included cardioversion, repeat ablation, or antiarrhythmic drug use after the blanking period. Other outcomes included mortality, hospitalization, and stroke. Outcomes were assessed after a 90-day blanking period at 3 and 5 years follow up.
Results
In the paroxysmal AF cohort, 422 patients remained in each group after matching. In the persistent AF cohort, 2,837 patients remained in each group after matching. After propensity score matching, baseline characteristics were well balanced between PVI-alone and PVI-plus groups in both the paroxysmal and persistent AF cohorts. Across both paroxysmal and persistent AF cohorts, there were no significant differences between PVI alone and PVI plus at either 3 or 5 years in cardioversion, repeat ablation, antiarrhythmic drug use, composite recurrence, mortality, hospitalization, or stroke. In the paroxysmal cohort, the composite recurrence endpoint was similar at 3 years (HR 1.09, 95% CI 0.88-1.34) and 5 years (HR 1.10, 95% CI 0.90-1.34). In the persistent cohort, composite recurrence was also similar at 3 years (HR 1.01, 95% CI 0.94-1.09) and 5 years (HR 1.01, 95% CI 0.94-1.10).
Conclusions
In patients with HFpEF undergoing first-time catheter ablation for paroxysmal or persistent AF, additional ablation beyond PVI was not associated with lower recurrence or improved major clinical outcomes compared with PVI alone. These findings suggest that PVI alone may be sufficient for many patients with HFpEF undergoing first-time AF ablation.
Zitieren
APA
Darzi, A. E., Chudy, A., Khalil, M. A., Massad, C. M., Khoury, C. E., Menassa, Y., Herbst, W., ATASI, M. M., Moersdorf, M., Feng, H., BAROUSSE, B., Pandey, A. C., Wanna, B., Kreidieh, O., Marashly, Q., Quintero, R. M., & Marrouche, N. (2026). Abstract 9328: Pulmonary Vein Isolation Alone vs Additional Ablation in Heart Failure with Preserved Ejection Fraction. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9328
Vancouver
Darzi AE, Chudy A, Khalil MA, Massad CM, Khoury CE, Menassa Y, et al. Abstract 9328: Pulmonary Vein Isolation Alone vs Additional Ablation in Heart Failure with Preserved Ejection Fraction. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9328
BibTeX
@article{Darzi2026,
author = {Darzi, Alex El and Chudy, Amy and Khalil, Michel Abou and Massad, Christian M and Khoury, Carlo El and Menassa, Yara and Herbst, William and ATASI, MOHAMMAD M and Moersdorf, Maximilian and Feng, Han and BAROUSSE, BENNETT and Pandey, Amitabh C and Wanna, Bassam and Kreidieh, Omar and Marashly, Qussay and Quintero, Rodolfo Montiel and Marrouche, Nassir},
title = {Abstract 9328: Pulmonary Vein Isolation Alone vs Additional Ablation in Heart Failure with Preserved Ejection Fraction},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9328}
}
EUVIMED